Accessibility Menu
Arrow-Thin-Down
S&P 500
6,738.44
+0.6%
+39.04
Arrow-Thin-Down
DJI
46,734.61
+0.3%
+144.20
Arrow-Thin-Down
NASDAQ
22,941.80
+0.9%
+201.40
Arrow-Thin-Down
Bitcoin
$111,175
+1.4%
+$1,578
Arrow-Thin-Down
AAPL
$259.58
+0.4%
+$1.13
Arrow-Thin-Down
AMZN
$221.09
+1.4%
+$3.14
Arrow-Thin-Down
GOOG
$253.73
+0.5%
+$1.2
Arrow-Thin-Down
META
$734
+0.1%
+$0.59
Arrow-Thin-Down
MSFT
$520.56
+0.0%
+$0.02
Arrow-Thin-Down
NVDA
$182.16
+1.0%
+$1.88
Arrow-Thin-Down
TSLA
$448.95
+2.3%
+$9.98
Daily Stock GainersDaily Stock LosersMost Active Stocks
Outlook Therapeutics Stock Quote

Outlook Therapeutics (NASDAQ: OTLK)

$1.31
(-2.6%)
-0.04
Price as of October 23, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$1.3
Daily Change
(-2.6%) $0.04
Day's Range
$1.28 - $1.34
Previous Close
$1.3
Open
$1.34
Beta
1.10
Volume
941,443
Average Volume
3,789,947
Sector
Health Care
Market Cap
57.7M
Market Cap / Employee
$1.30M
52wk Range
$0.79 - $6.98
Revenue
-
Gross Margin
0.63%
Dividend Yield
N/A
EPS
-$1.09
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Outlook Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
OTLK-75.33%-91.88%-39.46%-100%
S&P+16.23%+94.45%+14.22%+225%

Outlook Therapeutics Company Info

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

News & Analysis

Featured Article

Outlook Therapeutics Reports Q3 Revenue

Motley Fool Markets Team  |  Aug 14, 2025
Featured Article

Why Shares of Outlook Therapeutics Rose Tuesday

The healthcare stock hit a 52-week high for the second consecutive day.

James Halley  |  Jun 6, 2023

Financial Health

General

Q2 2025YOY Change
Revenue$1.51M0.0%
Gross Profit$1.04M3713.6%
Gross Margin68.83%0.0%
Market Cap$68.57M-60.3%
Market Cap / Employee$2.98M0.0%
Employees230.0%
Net Income-$20.15M-145.4%
EBITDA-$15.72M19.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$8.90M-72.2%
Accounts Receivable$1.75M0.0%
Inventory4.10.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$20.64M7826.9%
Short Term Debt$14.06M-56.7%

Ratios

Q2 2025YOY Change
Return On Assets-125.04%80.4%
Return On Invested Capital-303.97%-73.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$11.90M39.0%
Operating Free Cash Flow-$11.90M39.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-1.49-0.62-0.60-1.6234.02%
Price to Sales39.28-
Price to Tangible Book Value-1.49-0.62-0.60-1.6234.02%
Enterprise Value to EBITDA-6.24-3.30-5.13-5.40-44.08%
Total Debt$29.74M$31.03M$33.32M$34.70M6.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services